On-demand biomanufacturing of protective conjugate vaccines

Jessica C. Stark, Thapakorn Jaroentomeechai, Tyler D. Moeller, Jasmine M. Hershewe, Katherine F. Warfel, Bridget S. Moricz, Anthony M. Martini, Rachel S. Dubner, Karen J. Hsu, Taylor C. Stevenson, Bradley D. Jones, Matthew P. DeLisa, Michael C. Jewett*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Conjugate vaccines are among the most effective methods for preventing bacterial infections. However, existing manufacturing approaches limit access to conjugate vaccines due to centralized production and cold chain distribution requirements. To address these limitations, we developed a modular technology for in vitro conjugate vaccine expression (iVAX) in portable, freeze-dried lysates from detoxified, nonpathogenic Escherichia coli. Upon rehydration, iVAX reactions synthesize clinically relevant doses of conjugate vaccines against diverse bacterial pathogens in 1 hour. We show that iVAX-synthesized vaccines against Francisella tularensis subsp. tularensis (type A) strain Schu S4 protected mice from lethal intranasal F. tularensis challenge. The iVAX platform promises to accelerate development of new conjugate vaccines with increased access through refrigeration-independent distribution and portable production.

Original languageEnglish (US)
Article numbereabe9444
JournalScience Advances
Issue number6
StatePublished - Feb 3 2021

ASJC Scopus subject areas

  • General


Dive into the research topics of 'On-demand biomanufacturing of protective conjugate vaccines'. Together they form a unique fingerprint.

Cite this